by kati.sallinen@desentum.fi | Feb 18, 2026 | News
A scientific paper about the mechanism of peanut allergy has been published in the renowned journal Allergy by the research group of the University of Eastern Finland and Desentum. The main peanut allergen Ara h 2 was crystallized together with an IgE antibody Fab...
by kati.sallinen@desentum.fi | Jan 21, 2026 | News
Desentum, a clinical-stage biopharmaceutical company developing novel allergen immunotherapies, today announced that its Phase 2 clinical study evaluating DM‑101PX for the treatment of birch pollen allergy has completed enrolment. 97 participants have been randomised...
by kati.sallinen@desentum.fi | Dec 2, 2025 | News
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, announced today that the first trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy....
by kati.sallinen@desentum.fi | Aug 27, 2025 | News
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a Phase 2 clinical study with DM-101PX, an investigational immunotherapeutic treatment for birch pollen allergy. Approximately 100 birch pollen allergic adults will...
by kati.sallinen@desentum.fi | May 16, 2025 | News
All three abstracts submitted by Desentum have been accepted for oral presentations at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Glasgow, UK, on Jun 13–16, 2025. Two of the presentations will showcase the...